Literature DB >> 22086193

OCT4 pseudogenes present in human leukemia cells.

Xiaoping Guo1, Yongmin Tang.   

Abstract

The transcription factor OCT4 is expressed in embryonic stem cells (ESCs) and has been considered as a main regulator in maintaining pluripotency of ESCs. Several studies have showed OCT4 expression in human solid tumor and adult stem or progenitor cells. However, whether OCT4 is expressed in normal hematopoietic system including the peripheral blood and bone marrow remains controversial. Furthermore, the functional expression of OCT4 in leukemia cells and its potential significance in leukemia studies have been poorly defined. The aim of this study was to examine and analyze the genuine expression of OCT4 in human leukemia cells by means of RT-PCR, flow cytometry, PCR product sequencing and alignment with NCBI BLAST and DNAMAN software. The full lengths of the putative OCT4 genes were amplified in 2/9 leukemia cell lines and 7/49 leukemia patients' samples. However, many base mutations in putative OCT4 positive samples were found. Sequence alignment analysis showed a higher similarity between the putative OCT4 PCR products and the pseudogenes in chromosomes 1 and 8. The positive rates of OCT4 protein detected with flow cytometry were low, and almost all of them were less than 10% of positivity. A very small fraction of leukemia stem cells with OCT4 protein expression was found. We conclude that OCT4 pseudogenes in chromosomes 1 and 8 present in the panel of leukemia cells tested and the OCT4 protein is rarely detected with flow cytometry in leukemia cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22086193     DOI: 10.1007/s10238-011-0163-4

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  36 in total

Review 1.  OCT4: biological functions and clinical applications as a marker of germ cell neoplasia.

Authors:  L Cheng; M-T Sung; P Cossu-Rocca; T D Jones; G T MacLennan; J De Jong; A Lopez-Beltran; R Montironi; L H J Looijenga
Journal:  J Pathol       Date:  2007-01       Impact factor: 7.996

2.  Analysis of OCT4 expression in an extended panel of human tumor cell lines from multiple entities and in human mesenchymal stem cells.

Authors:  T Mueller; J Luetzkendorf; K Nerger; H-J Schmoll; L P Mueller
Journal:  Cell Mol Life Sci       Date:  2009-02       Impact factor: 9.261

3.  OCT4 spliced variants are differentially expressed in human pluripotent and nonpluripotent cells.

Authors:  Yaser Atlasi; Seyed J Mowla; Seyed A M Ziaee; Paul J Gokhale; Peter W Andrews
Journal:  Stem Cells       Date:  2008-09-11       Impact factor: 6.277

4.  Oct4 and its pseudogenes confuse stem cell research.

Authors:  Stefanie Liedtke; Jürgen Enczmann; Simon Waclawczyk; Peter Wernet; Gesine Kögler
Journal:  Cell Stem Cell       Date:  2007-10-11       Impact factor: 24.633

5.  POU5F1 isoforms show different expression patterns in human embryonic stem cells and preimplantation embryos.

Authors:  Greet Cauffman; Inge Liebaers; André Van Steirteghem; Hilde Van de Velde
Journal:  Stem Cells       Date:  2006-08-17       Impact factor: 6.277

6.  Reprogramming of human somatic cells to pluripotency with defined factors.

Authors:  In-Hyun Park; Rui Zhao; Jason A West; Akiko Yabuuchi; Hongguang Huo; Tan A Ince; Paul H Lerou; M William Lensch; George Q Daley
Journal:  Nature       Date:  2007-12-23       Impact factor: 49.962

7.  Human Oct3 gene family: cDNA sequences, alternative splicing, gene organization, chromosomal location, and expression at low levels in adult tissues.

Authors:  J Takeda; S Seino; G I Bell
Journal:  Nucleic Acids Res       Date:  1992-09-11       Impact factor: 16.971

8.  Serum deprivation of human marrow stromal cells (hMSCs) selects for a subpopulation of early progenitor cells with enhanced expression of OCT-4 and other embryonic genes.

Authors:  Radhika R Pochampally; Jason R Smith; Joni Ylostalo; Darwin J Prockop
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

9.  Embryonic stem cell markers expression in cancers.

Authors:  Matthieu Schoenhals; Alboukadel Kassambara; John De Vos; Dirk Hose; Jérôme Moreaux; Bernard Klein
Journal:  Biochem Biophys Res Commun       Date:  2009-03-04       Impact factor: 3.575

10.  Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia.

Authors:  Adolfo A Ferrando; Donna S Neuberg; Jane Staunton; Mignon L Loh; Christine Huard; Susana C Raimondi; Fred G Behm; Ching Hon Pui; James R Downing; D Gary Gilliland; Eric S Lander; Todd R Golub; A Thomas Look
Journal:  Cancer Cell       Date:  2002-02       Impact factor: 31.743

View more
  5 in total

Review 1.  Octamer-binding transcription factors: genomics and functions.

Authors:  Feng-Qi Zhao
Journal:  Front Biosci (Landmark Ed)       Date:  2013-06-01

2.  Pseudogene BMI1P1 expression as a novel predictor for acute myeloid leukemia development and prognosis.

Authors:  Ling-Yu Zhou; Ling-Ling Zhai; Jia-Yu Yin; Minse Evola-Deniz Vanessa; Jiao Zhou; Jing Zhang; Xi Tang; Jiang Lin; Jun Qian; Zhao-Qun Deng
Journal:  Oncotarget       Date:  2016-07-26

3.  Prognostic Nomogram of Prognosis-Related Genes and Clinicopathological Characteristics to Predict the 5-Year Survival Rate of Colon Cancer Patients.

Authors:  Chao Huang; Jiefeng Zhao; Zhengming Zhu
Journal:  Front Surg       Date:  2021-06-16

4.  Pseudogenes as weaknesses of ACTB (Actb) and GAPDH (Gapdh) used as reference genes in reverse transcription and polymerase chain reactions.

Authors:  Yuan Sun; Yan Li; Dianzhong Luo; D Joshua Liao
Journal:  PLoS One       Date:  2012-08-22       Impact factor: 3.240

5.  New insights into long noncoding RNAs and pseudogenes in prognosis of renal cell carcinoma.

Authors:  Binghai Chen; Chengyue Wang; Jin Zhang; Yang Zhou; Wei Hu; Tao Guo
Journal:  Cancer Cell Int       Date:  2018-10-11       Impact factor: 5.722

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.